PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportssleep initiation and maintenance disorders
MeSH D007319 - sleep initiation and maintenance disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D020919:Intrinsic sleep disorders
0 Companies
0 Drugs
Success rate
D007319: 
Sleep initiation and maintenance disorders
D034062:Fatal familial insomnia
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDiphenhydramine Diphenhydramine  1982-01-01   
Eszopiclone Eszopiclone  2011-05-23   
Trazodone Trazodone  1987-12-11   
Zaleplon Zaleplon  2008-06-06   
Zolpidem Zolpidem  2007-04-23   
Glenmark PharmaceuticalsEszopiclone Eszopiclone  2014-04-15   
MylanDiphenhydramine Diphenhydramine  2005-07-12   
Doxylamine, Pyridoxine Doxylamine Pyridoxine  2020-07-06   
Eszopiclone Eszopiclone  2013-03-26   
Trazodone Trazodone  2009-06-02   
Zolpidem Zolpidem  2007-04-23   
ViatrisZolpidem Edluar 2027-04-06 2009-03-13   
NATCO PharmaTrazodone Trazodone  1991-02-27   
Zaleplon Zaleplon  2008-06-06   
XiromedRamelteon Ramelteon  2022-11-25   
PerrigoDiphenhydramine Antitussive  1987-04-10   
Diphenhydramine Diphenhydramine  1982-01-01   
Ibuprofen, Diphenhydramine Ibuprofen Diphenhydramine  2008-12-22   
Naproxen, Diphenhydramine Naproxen Diphenhydramine  2019-05-10   
P&L Developments (PLD)Naproxen, Diphenhydramine Naproxen Diphenhydramine  2019-01-25   
GSKIbuprofen, Diphenhydramine Advil 2022-01-17 2005-12-21   
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
74%
17/23
Phase 2
57%
16/28
Phase 3
68%
40/59
Approved: 25Overall Success rate: 29%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use